-
Its back to the research drawing board in the search for more treatment options for genital herpes. A clinical trial of an experimental drug, resiquimod, has been suspended since preliminary data showed it was not as effective as expected.
-
The news is in from the worlds first large-scale trial of a HIV vaccine, and it isnt good: The vaccine failed to achieve a statistically significant reduction of HIV infection within its study population as a whole.
-
Epidemiological evidence presented at a recent Bethesda, MD-based National Cancer Institute (NCI) workshop could help end a longstanding debate on the question of induced abortion and risk of breast cancer.
-
Scientists recently conducted an international survey to explore womens willingness to use a contraceptive that induces amenorrhea.
-
Four years after its initial announcement to revive the Today contraceptive sponge, the company responsible for its rebirth finally has released the product in Canada and says it is pressing for Food and Drug (FDA) approval to market the device over the counter in the United States.
-
Without fanfare, the Bush administration has issued an important report to Congress on nondirective pregnancy options counseling in family planning clinics. Specifically, the report sought to assess the extent to which adoption information and referral is provided as part of nondirective counseling in publicly funded clinics.
-
If the number of men on your patient rosters is low, take a look at the approach used by Planned Parenthood of San Antonio and South Central Texas. In the first year of its marketing initiative, the number of its male patients nearly doubled from 2% to 3.7% of total patients served.
-
Check out the following Internet resources for more information on hormone therapy.
-
Family planning clinicians have found their care of postmenopausal women has changed dramatically since the July 2002 cessation of the estrogen/progestin arm of the Womens Health Initiative (WHI). The estrogen/progestin arm of the landmark study was halted after findings showed that the overall health risk, particularly of cardiovascular disease and breast cancer, from taking estrogens with progestin was greater than the benefits of lowering the risk of colon cancer and bone fractures.
-
Enter abstracts for ARHP annual conference; New payment options announced for Mirena